Xiaoping Ning

Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial

Michel D. Ferrari, Hans‐Christoph Diener, Xiaoping Ning et al. · The Lancet · 2019 · 418 citations

Cluster Headache, Documented Failure, Clinical Trials +7

Long-term safety, tolerability, and efficacy of fremanezumab in migraine

Peter J. Goadsby, Stephen D. Silberstein, Paul Yeung et al. · Neurology · 2020 · 159 citations · Full text

Risperidone Dosing in Children and Adolescents with Autistic Disorder: A Double-Blind, Placebo-Controlled Study

Justine Kent, Stuart Kushner, Xiaoping Ning et al. · Journal of Autism and Developmental Disorders · 2012 · 147 citations

Psychiatry, Psychotropic Medication, Pediatrics +7

Efficacy and safety of fremanezumab for episodic migraine prevention: Multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group trial in Japanese and Korean patients

Fumihiko Sakai, Norihiro Suzuki, Byung‐Kun Kim et al. · Headache The Journal of Head and Face Pain · 2021 · 103 citations · Full text

Efficacy and safety of fremanezumab for chronic migraine prevention: Multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group trial in Japanese and Korean patients

Fumihiko Sakai, Norihiro Suzuki, Byung‐Kun Kim et al. · Headache The Journal of Head and Face Pain · 2021 · 93 citations · Full text